

**Challenges in Safety, Supply, Market Competition, and Regulation of Infant Formula in the
United States**

Meeting 19 – Supply Chain Data

January 4, 2024

1:30 – 2:30 pm

Annotated Agenda

Open Session

1:30 pm **Welcome and Chair Statement**
Barbara Schneeman, Committee Chair

1:35 pm **Discussion with 21 Forward**
Moderated by Ravi Anupindi

- *William J. Kassler, MD, MPH, Fmr Chief Medical Officer, Chief Medical Officer, Palantir Technologies*
- *Philomena Fritz, Healthcare and Public Health Strategy & Growth, Palantir Technologies*

Moderated Questions

1. How was 21 Forward used during the infant formula shortage?
2. What sets of data (e.g, volume & inventory across different SC stages, Plant quality, etc.) and from which parties - don't need names but which segments of the extended SC - are they using for these features?
3. What is the granularity - in time, across products, WIC vs non-WIC - of these data?
4. Is the data coming directly from the supply chain actors or from 3rd party sources?
5. What are the current capabilities of 21 Forward?
6. What are some future capabilities 21 Forward wishes to build?

2:30 pm **Adjourn Open Session**